A Randomized Controlled Trial Testing the Effect of the Youth Mindful Awareness Program on Negative Affect (YMAP2).
Launched by VANDERBILT UNIVERSITY · Jul 24, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The YMAP2 clinical trial is studying how an online mindfulness program can help reduce feelings of stress and anxiety in young people aged 12 to 17 who are at risk for these issues. Participants will be randomly assigned to one of three groups: one that practices mindfulness, another that receives supportive activities, and a third that does not receive any intervention. The researchers will evaluate the participants' mood and emotional health before, immediately after, and six months after the program to see if the mindfulness program helps improve their feelings and reduce anxiety.
To be eligible for this trial, young people must be between 12 and 17 years old, have permission from a parent or guardian, and live in Illinois, California, or Tennessee. It's important to note that those who currently have serious anxiety or depression, substance use issues, or certain other mental health diagnoses will not be able to participate. If chosen to take part, participants can expect to engage in a series of online sessions focused on mindfulness, which involves techniques to help them stay present and manage their emotions better. Overall, this trial aims to find effective ways to support young people's mental health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ages 12, 13, 14, 15, 16, 17
- • Parental Consent
- • Participant Assent
- • Live in Illinois, California, or Tennessee
- Exclusion Criteria:
- • current diagnosis of an anxiety or depressive disorder with significant clinical impairment
- • current alcohol or substance use disorder
- • current serious suicidal ideation or behavior
- • lifetime diagnosis of bipolar disorder, schizophrenia, autism, conduct disorder, or developmental delay
- • reading level below 4th grade
- • not English speaking at a level that would allow them to participate in the intervention and assessments
About Vanderbilt University
Vanderbilt University is a prestigious research institution renowned for its commitment to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on collaboration across various disciplines, Vanderbilt leverages its state-of-the-art facilities and a diverse team of experts to conduct rigorous clinical studies. The university is dedicated to improving patient outcomes by exploring novel therapeutic interventions and enhancing understanding of disease mechanisms. Through its robust clinical research infrastructure, Vanderbilt University aims to contribute significantly to the scientific community and the development of effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Nashville, Tennessee, United States
Evanston, Illinois, United States
Patients applied
Trial Officials
Megan M Saylor, PhD
Study Chair
Vanderbilt University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported